



PATENT

Case Docket No. ABGENIX.091A

Date: November 5, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Gudas et al.
Appl. No. : 10/644,277
Filed : August 19, 2003
For : ANTIBODIES DIRECTED TO
MONOCYTE CHEMO-
ATTRACTANT PROTEIN-1
(MCP-1) AND USES THEREOF
Examiner : Not Assigned
Group Art Unit : Not Assigned

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

November 5, 2003

(Date)

Michael L. Fuller, Reg. No. 36,516

TRANSMITTAL LETTER


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 listing eight (8) references which are also enclosed.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Michael L. Fuller
Registration No. 36,516
Attorney of Record
Customer No. 20,995
(619) 235-8550

**INFORMATION DISCLOSURE STATEMENT**

Applicant : Gudas et al.
App. No. : 10/644,277
Filed : August 19, 2003
For : ANTIBODIES DIRECTED TO
MONOCYTE CHEMO-ATTRACTANT
PROTEIN-1 (MCP-1) AND USES
THEREOF
Examiner : Not Assigned
Group Art Unit : Not Assigned


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing eight (8) references which are also enclosed. This Information Disclosure Statement is being filed with an RCE or within three months of the filing date of this application and no fee is required in accordance with 37 C.F.R. § 1.97(b)(1), (b)(2), or (b)(4).

Respectfully submitted,
KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: November 5, 2003

By: 
Michael L. Fuller
Registration No. 36,516
Attorney of Record
Customer No. 20,995
(619) 235-8550

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ABGENIX.091AAPPLICATION NO.
10/644,277INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Gudas et al.FILING DATE
August 19, 2003GROUP
Not Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	1.	WO 01/89565	11/29/01					

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	2.	Bradwell et al., "Control of hypercalcaemia of parathyroid carcinoma by immunisation," <i>Lancet</i> , 353: 370-373 (1999)
	3.	Hemmerich et al., "Identification of Residues in the Monocyte Chemotactic Protein-1 That Contact the MCP-1 Receptor, CCR2," <i>Biochemistry</i> , 38: 13013-13025 (1999)
	4.	Jarnagin et al., "Identification of Surface Residues of the Monocyte Chemotactic Protein 1 That Affect Signaling through the Receptor CCR2," <i>Biochemistry</i> , 38: 16167-16177 (1999)
	5.	Logue et al., "Production and characterisation of monoclonal antibodies to parathyroid hormone (1-34)," <i>J. Immunol. Methods</i> , 137: 159-166 (1991)
	6.	Magerlein et al., "Production of Sequence Specific Polyclonal Antibodies to Human Parathyroid Hormone 1-37 by Immunization with Multiple Antigenic Peptides," <i>Drug Res.</i> , 48: 783-787 (1998)
	7.	Vieira et al., "Monoclonal Antibodies to Bovine Parathyroid Hormone: Production and Characterization," <i>Braz. J. Med. Biol. Res.</i> , 21: 1005-1011 (1988)
	8.	Visser et al., "Production and Characterization of Antisera to Synthetic 1-34 Human Parathyroid Hormone Fragments: Possible Implications for the Correctness of Proposed Structures," <i>Acta Endocrinol.</i> , 90: 90-102 (1979)

S:\DOCS\SRG\SRG-1923.DOC\082803\vo

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	